Immunic Q1 2023 Earnings Report
Key Takeaways
Immunic reported positive results from the Phase 1b clinical trial of IMU-856 in celiac disease, demonstrating improvements in histology, disease symptoms, biomarkers, and nutrient absorption. The company is preparing for a Phase 2b clinical trial of IMU-856 in celiac disease patients. Additionally, data from the maintenance phase of the Phase 2b CALDOSE-1 trial of vidofludimus calcium in ulcerative colitis showed statistically significant activity compared to placebo. The company expects an interim biomarker analysis from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive MS in the second half of 2023.
Reported positive data from the maintenance phase of the phase 2b CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis (UC).
Announced positive results from our phase 1b clinical trial of IMU-856 in patients with celiac disease.
Preparing for a phase 2b clinical trial of IMU-856 in ongoing active celiac disease patients.
Next value inflection point will be a second half 2023 interim biomarker analysis of our phase 2 CALLIPER trial in progressive MS.
Immunic
Immunic
Forward Guidance
Immunic expects its cash, cash equivalents and investments to fund operations into the fourth quarter of 2024.